NCT05019105View on ClinicalTrials.gov

Phase 1 ALKS 1140 in Healthy Adults

PHASE1TerminatedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

October 13, 2021

Primary Completion Date

August 23, 2022

Study Completion Date

August 23, 2022

Conditions

Central Nervous System Diseases

Interventions

DRUG

Placebo

Oral matching placebo

DRUG

ALKS 1140

Active oral dose of ALKS 1140

Trial Locations (1)

Unknown

Alkermes Clinical Investigative Site, Brisbane

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Alkermes, Inc.

INDUSTRY